• 1
    EASL Clinical Practice Guidelines. Management of hepatitis C virus infection. J Hepatol 2011; 55: 24564.
  • 2
    Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 2012; 26: 40112.
  • 3
    Hanafiah KM, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to hepatitis C virus seroprevalence. Hepatology 2012; 57: 133342.
  • 4
    Sarrazin C, Hezode C, Zeuzem S, Pawlotsky JM. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012; 56(Suppl. 1): S88100.
  • 5
    Dusheiko G, Wedemeyer H. New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye. Gut 2012; 61: 164752.
  • 6
    Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 143344.
  • 7
    Sarrazin C, Berg T, Cornberg M, et al. [Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C]. Z Gastroenterol 2012; 50: 5772.
  • 8
    Harrington PR, Zeng W, Naeger LK. Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. Hepatology 2012; 55: 104857.
  • 9
    Chevaliez S, Pawlotsky JM. How to use virological tools for optimal management of chronic hepatitis C. Liver Int 2009; 29(Suppl. 1): 914.
  • 10
    Chevaliez S, Pawlotsky JM. Virological techniques for the diagnosis and monitoring of hepatitis B and C. Ann Hepatol 2009; 8: 712.
  • 11
    Zitzer H, Heilek G, Truchon K, et al. Second-generation Cobas AmpliPrep/Cobas TaqMan HCV quantitative test for viral load monitoring: a novel dual-probe assay design. J Clin Microbiol 2013; 51: 5717.
  • 12
    Wedemeyer H, Kessler HH, Michel-Treil V, et al. The ExPECT study: an international multicenter clinical trial evaluating low HCV RNA viremia with the COBAS AmpliPrep/COBAS TaqMan HCV Test, v2.0 compared to assays used in routine clinical practise and in drug trials. Hepatology 2012; 56(Suppl.): 676A7A.
  • 13
    Maasoumy B, Port K, Markova AA, et al. Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS ONE 2013; 8: e55285.
  • 14
    Hezode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with hcv-cirrhosis in a multicentre cohort of the french early access programme (anrs co20-cupic) – nct01514890. J Hepatol 2013; 59: 43441.
  • 15
    Vermehren J, Aghemo A, Pfeiffer KH, et al. Undetectable HCV-RNA in telaprevir-treated patients: low concordance between two highly sensitive real-time pcr assays. J Hepatol 2013; 58(Suppl.): 208.